Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics:
- Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00)
- Other ADCs under investigation for patients with ovarian cancer (20:05)
- Mechanism of action and activity of upifitamab rilsodotin (UpRi) for patients with pretreated ovarian cancer (23:27)
- Emerging strategies for patients with platinum-resistant ovarian cancer (29:53)
- Rationale for the discontinuation of clinical development of UpRi (33:17)
CME information and select publications
Research To Practice | Oncology Videos